NCT01740024已完成2 期
An Open-label, Multicentre Study Comparing the Biological Potency of the Native, Depigmented and Depigmented Polymerized Cat Epithelial Allergenic Extracts.
Laboratorios Leti, S.L.4 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2012年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
- 试验地点
- 4
- 主要终点
- Wheal size area (mm2)elicited on the skin after the dose-response prick-test
研究概览
简要总结
The primary objective of this clinical trial is to quantify the loss of in vivo biological potency of a depigmented polymerized (DPP) allergenic cat epithelial extract versus the native allergenic extract (N).
详细描述
This is an open-label, non-randomized phase II clinical trial.
Three different concentrations of three different cat epithelial allergenic extracts, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride and a glycerated phenol saline solution, respectively, will be tested in every subject on the volar surface of the forearm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A subject will be eligible for inclusion in the study only if all of the following criteria are met:
- •The subject (and/or legal representative, where applicable) has given written, signed and dated informed consent.
- •Subjects of either sex and of any race or ethnic group.
- •Age > 18 years and < 60 years on the day of inclusion in the study.
- •Positive clinical history of allergy to cat epithelia (i.e., rhinitis, conjunctivitis, rhinoconjunctivitis, asthma, urticaria, etc. ).
- •A positive prick-test (mean diameter of papule ≥ 3 mm or area of papule ≥ 7 mm2) with a commercial extract of cat epithelium. The results of the prick-test will be valid if they were obtained in the year prior to inclusion of the subject in the study.
- •A positive specific IgE test (> 0.70 KU/l) for cat epithelium. The results of the IgE test will be valid if they were obtained in the year prior to inclusion of the subject in the study.
排除标准
- •A subject will NOT be eligible for inclusion in the study if any of the following criteria are met:
- •Immunotherapy in the last 5 years involving allergens known to be able to interfere with the test allergen (e.g., cat extract).
- •Use of drugs that can interfere with the skin response before and during the study (e.g., antihistamines), within the intervals established in section 9.1 and appendix
- •Treatment with any of the following medicines: tricyclic or tetracyclic antidepressants or MAOIs (Monoamine oxidase inhibitors), beta-blockers or chronic use of oral corticosteroids or use of corticosteroids via either the oral or the parenteral route in repeated and intermittent dosing regimens (> 10 mg/day of prednisone or equivalent).
- •Pregnant or nursing women and women with a positive pregnancy test in visit
- •Dermographism affecting the skin of the test site, in either of the two visits to the study centre.
- •Atopic dermatitis affecting the skin of the test site, in either of the two visits to the study centre.
- •Urticaria affecting the skin of the test site, in either of the two visits to the study centre.
- •Clinically relevant immune system diseases (both autoimmune disorders and immune deficiencies). (Hashimoto's thyroiditis with hypothyroidism well controlled through thyroid hormone therapy does not necessarily represent a contraindication. Graves' disease (hyperthyroidism) would be an exclusion criterion due to the potential risk in the event adrenaline must be used.)
- •Serious uncontrolled diseases that may increase the safety risk of the subjects participating in the study, including but not limited to the following: heart failure, serious or uncontrolled respiratory diseases, endocrine disorders, clinically relevant liver or kidney diseases, or haematological disorders.
- •Patents with diseases or conditions that limit adrenaline use (coronary disease, severe arterial hypertension, etc.).
- •Serious psychiatric, psychological or neurological problems.
- •Medication, alcohol or illegal drug abuse in the last year.
- •Participation in any other clinical trial during the 30 days (or 5 times the biological half-life of the investigational product - whichever is longest) prior to inclusion of the subject in this study.
结局指标
主要结局
Wheal size area (mm2)elicited on the skin after the dose-response prick-test
时间窗: Test sites should be inspected and recorded 15-20 min after application
Wheal size area (mm2)elicited on the skin after the dose-response prick-test, in duplicate, of the native and depigmented polymerized cat epithelial allergenic extracts, together with the area of the wheals induced by the positive and negative controls.
次要结局
- Wheal siza area (mm2)elicited on the skin after the dose-response prick-test(Test sites should be inspected and recorded 15-20 min after application)
- Wheal size area (mm2)elicited on the skin after the dose-response prick-test(Test sites should be inspected and recorded 15-20 min after application)
- Determine the HEP dose of the native (N) cat epithelial allergenic extract(Wheals will be elicited in visit 2. CRFs will be retrieved, measured in-house and filed back in the site before study closure (maximum 3 months after being elicited).)
- Loss of in vitro potency of the cat epithelial allergenic extracts(Blood will be collected in visit 2. Serum samples will be analyze once every sample is received. The samples will be analyzed at most 12 months after received)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet FormulationBioequivalenceNCT03708133Bayer24
已完成
1 期
A Study of Subcutaneous Lecanemab in Healthy ParticipantsHealthy VolunteersNCT05045716Eisai Inc.60
已完成
1 期
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal MelanomaUveal MelanomaChoroid NeoplasmNCT02771340Iconic Therapeutics, Inc.10
招募中
2 期
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06055959UCB Biopharma SRL8
已完成
4 期
An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative PainPostoperative PainNCT00465647Purdue Pharma LP116